IL-33 is Required for Behavioral Deficits in a Murine Model of Systemic Lupus Erythematosus Through Regulation of Microglia Glycolysis
Our findings identify IL-33 as a key contributor to dNPSLE pathogenesis, driving microglial activation and phagocytosis via glycolytic reprogramming. These results highlight IL-33 as a potential therapeutic target for dNPSLE, warranting further investigation into its clinical translation.
Authors
- Xiujiao Wang (ORCID: https://orcid.org/0000-0001-8349-7822)
- Nan Che (ORCID: https://orcid.org/0000-0002-6914-5174)
- F F Lu
- Rui Liu
- Mei Sun
Institutions
- Nanjing Medical University (CN)
Publication Details
- Journal
- CNS & Neurological Disorders - Drug Targets
- Published
- 2026-03-13
- DOI
- https://doi.org/10.2174/0118715273431664251202114653
- Primary Topic
- IL-33, ST2, and ILC Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00